Ranibizumab
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Biological Agent ->
Monoclonal Antibody ->
Monoclonal Antibody Anti-VEGF -> Ranibizumab
Ranibizumab Definition
A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.
Ranibizumab Synonyms
Ranibizumab, Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal rhuFab V2 Gamma1 Chain), Disulfide With Human-Mouse Monoclonal rhuFab V2 Light Chain, Lucentis, RANIBIZUMAB
Terms in Ranibizumab category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.